瑞慈醫療(01526.HK)以2.87億人幣悉售婦兒專科醫院60%股權
瑞慈醫療(01526.HK)公布,以2.87億元人民幣(下同)向和睦家醫療的成員公司悉售婦兒專科醫院「瑞慈水仙」全部股權的60%和瑞慈瑞靜的全部股權,金額可予調整,預期加價不超過1,200萬元。瑞慈瑞靜為一間綜合門診部,自註冊成立以來並無實質業務及並無錄得收益、利潤或總資產或淨資產。
完成後,公司將不再擁有瑞慈水仙及瑞慈瑞靜的任何股權,因此瑞慈水仙及瑞慈瑞靜將不再為公司附屬,而瑞慈水仙及瑞慈瑞靜的財務業績將不再併入集團綜合財務報表。公司估計將從出售事項中確認總未經審核收益近2.2億人民幣。
瑞慈醫療表示,瑞慈水仙為集團婦兒專科醫院業務旗下虧損的婦兒專科醫院之一,鑑於瑞慈水仙的過往財務表現,認為出售瑞慈水仙為集團提供了機會改善其財務表現,更好地利用其資源,專注於發展其他業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.